Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.

Whelton A.

J Hypertens Suppl. 2002 Sep;20(6):S31-5. Review.

PMID:
12683425
2.

Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S401-13.

3.

Current perspective on the cardiovascular effects of coxibs.

Konstam MA, Weir MR.

Cleve Clin J Med. 2002;69 Suppl 1:SI47-52. Review.

PMID:
12086293
4.

Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors.

Scheiman JM.

Cleve Clin J Med. 2002;69 Suppl 1:SI40-6. Review.

PMID:
12086292
6.
8.

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.

Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM; SUCCESS VI Study Group..

Am J Ther. 2001 Mar-Apr;8(2):85-95. Erratum in: Am J Ther 2001 May-Jun;8(3):220.

PMID:
11304662
9.

Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S414-27.

10.

An evidence-based evaluation of the gastrointestinal safety of coxibs.

Bombardier C.

Am J Cardiol. 2002 Mar 21;89(6A):3D-9D. Review.

PMID:
11909555
11.

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.

Hochberg MC.

Semin Arthritis Rheum. 2002 Dec;32(3 Suppl 1):4-14. Review.

PMID:
12528069
12.

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.

Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel DL, Quan H, Larson PJ, Schwartz JI, Musliner TA, Gertz BJ, Brater DC, Yao SL.

Ann Intern Med. 2000 Jul 4;133(1):1-9.

PMID:
10877734
13.
14.

Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?

Savage R.

Drugs Aging. 2005;22(3):185-200. Review.

PMID:
15813652
15.

Gastrointestinal safety of coxibs and outcomes studies: what's the verdict?

Laine L.

J Pain Symptom Manage. 2002 Apr;23(4 Suppl):S5-10; discussion S11-4. Review.

PMID:
11992743
16.

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.

Circulation. 2004 May 4;109(17):2068-73.

17.

Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.

Hawkey CJ, Jackson L, Harper SE, Simon TJ, Mortensen E, Lines CR.

Aliment Pharmacol Ther. 2001 Jan;15(1):1-9. Review.

18.

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators..

Arch Intern Med. 2005 Jan 24;165(2):161-8. Erratum in: Arch Intern Med. 2005 Mar 14;165(5):551.

PMID:
15668361
19.

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.

Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ, Gottesdiener KM, Laurenzi M, Redfern KJ, Brune K.

Clin Pharmacol Ther. 2002 Jul;72(1):50-61.

PMID:
12152004
20.

[COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].

Peretz A.

Rev Med Brux. 2001 Sep;22(4):A377-80. Review. French.

PMID:
11680204
Items per page

Supplemental Content

Support Center